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Abstract The cDNA and gene encoding human chondroitin 6-
sulfotransferase (C6ST) have been cloned. The expression of a
soluble recombinant form of the protein in COS-1 cells produced
an active sulfotransferase, which used as acceptor substrates
polymer chondroitin, various chondroitin sulfate isoforms and
chondroitin sulfate tetrasaccharides. The identification of the
reaction products demonstrated that the enzyme transferred
sulfate to position 6 of GalNAc in the GlcAL1-3GalNAc but not
the IdoAK1-3GalNAc nor the GlcAL1-3GalNAc(4-O-sulfate)
sequences. The human C6ST gene spans more than 20 kb and
consists of three exons. The protein-coding domain of the C6ST
gene is divided into two discrete exons.
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1. Introduction
Chondroitin sulfate proteoglycans, which consist of a core
protein with at least one covalently attached glycosaminogly-
can (GAG) chain, are distributed on the surfaces of most cells
and the extracellular matrix in virtually every tissue (for re-
views, see [1,2]). Despite the ubiquity of this family of mole-
cules, a wide variety of chondroitin sulfate proteoglycans with
characteristic sulfated GAG chains exhibit tissue-speci¢c and
developmentally regulated expression [3], and have been im-
plicated in the regulation and maintenance of cell prolifera-
tion, cytodi¡erentiation, and tissue morphogenesis [4]. In neu-
ral development, chondroitin sulfate governs developmentally
signi¢cant events such as cellular adhesion, migration, and
neurite outgrowth [5^8]. The molecular basis for the develop-
mentally regulated and tissue-speci¢c synthesis of chondroitin
sulfate, as well as other GAGs, has yet to be clari¢ed.
Chondroitin sulfate has a linear polymer structure that pos-
sesses repetitive, sulfated disaccharide units containing glucur-
onic acid (GlcA) and N-acetylgalactosamine (GalNAc) [1,2].
Since GAG structures are largely determined by the speci¢c-
ities of the sulfotransferases responsible for their synthesis, it
is presumed that the di¡erential expression of the enzymes is
the key for the controlled synthesis of GAGs. Despite the
growing number of sulfotransferase cDNAs which have
been cloned, limited information is available about the organ-
ization and regulation of the expression of sulfotransferase
genes.
The major chondroitin sulfate found in the mammalian
tissues bears sulfate groups at position 4 or 6 of GalNAc
residues. It was reported that the ratio of 4-sulfation/6-sulfa-
tion changed during the development of chicken and human
epiphyseal cartilage and rat skin [4,9^11]. We recently dem-
onstrated that the ratio of 4-sulfation/6-sulfation in the em-
bryonic chick brain changes with development and that the
relative levels of the speci¢c sulfotransferase activities are
closely coordinated with the relative changing levels of the
speci¢c chondroitin sulfate structures [12]. These ¢ndings sug-
gested that the expression of sulfotransferases is a predomi-
nant factor regulating the sulfation pro¢le of chondroitin sul-
fate structures. Among the sulfotransferases involved in the
biosynthesis of chondroitin sulfate, the cDNAs encoding
chondroitin 6-sulfotransferase (C6ST), which catalyzes the
transfer of sulfate from PAPS to position 6 of the GalNAc
residue, were recently cloned from chicken and mouse [13,14].
In addition, during the preparation of this article, a report of
the human C6ST cDNA sequence appeared [15]. However,
the precise speci¢cities of these recombinant enzymes and
these gene organizations have not been described. In this re-
port, we have characterized the human recombinant C6ST
and determined the genomic organization.
2. Materials and methods
2.1. Materials
[35S]PAPS and unlabeled PAPS were purchased from New England
Nuclear (Boston, MA, USA) and Sigma Chemicals (St. Louis, MO,
USA), respectively. Chondroitin (a chemically desulfated derivative
of whale cartilage chondroitin sulfate A), various chondroitin sulfate
isoforms and four unsaturated standard disaccharides derived
from chondroitin sulfate, i.e. v4;5HexAK1-3GalNAc(4-O-sulfate),
v4;5HexAK1-3GalNAc(6-O-sulfate), v4;5HexAK1-3GalNAc(4,6-O-di-
sulfate), and v4;5HexA(2-O-sulfate)K1-3GalNAc(6-O-sulfate), chon-
droitinase ABC (EC 4.2.2.4), chondro-4-O-sulfatase (EC 3.1.6.9),
and chondro-6-O-sulfatase (EC 3.1.6.10) were purchased from Seika-
gaku Corp. (Tokyo, Japan). Tetrasaccharides used as acceptors (see
Table 2) were isolated by high-performance liquid chromatography
(HPLC) after the hyaluronidase digestion of chondroitin, king crab
cartilage chondroitin sulfate K and bovine bronchial cartilage chon-
droitin sulfate as described [16,17]. They were structurally character-
ized enzymatically and also by 500-MHz 1H NMR spectroscopy when
required. HITRAP Desalting columns were obtained from Amersham
Pharmacia Biotech (Uppsala, Sweden). All other reagents and chem-
icals were of the highest quality available.
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2.2. Cloning of the human C6ST cDNA
Chick C6ST cDNA was ¢rst ampli¢ed by polymerase chain reac-
tion (PCR) using a 5P primer, 5P-CGAGAAGGAAAACAACTTCA-
3P (the nucleotide sequence corresponding to 321^340 of the cDNA
for chick C6ST [13]), and the 3P primer, 5P-CTCGGGCGCTGGTGA-
GAT-3P (the nucleotide sequence corresponding to 769^786), using
chick embryo brain cDNA as a template as described [12]. A human
placenta cDNA library in a Vgt 10 phage vector (Clontech, Palo Alto,
CA, USA) was screened with the cloned chick C6ST cDNA fragment.
Three positive clones were plaque-puri¢ed, and then the insert cDNA
fragments were subcloned into Bluescript plasmid vectors (Stratagene,
La Jolla, CA, USA) and sequenced using a 377 DNA sequencer (PE
Applied Biosystems, Foster City, CA, USA). To obtain the 5P and 3P
ends of the C6ST cDNA, a cloning strategy of rapid ampli¢cation of
cDNA ends (RACE) was employed according to the manufacturer’s
instructions (5P/3P RACE kit, Boehringer Mannheim, Mannheim,
Germany), using 0.2 Wg of human placenta poly(A) RNA as a tem-
plate. The nucleotide sequence of the ampli¢ed cDNA was determined
in the DNA sequencer. Several clones were sequenced to compensate
for misreading by EX Taq polymerase (Takara Shuzo Co., Kyoto,
Japan).
2.3. Construction of a soluble form of the human C6ST
A truncated form of C6ST, lacking the ¢rst N-terminal 48 amino
acids of the C6ST, was ampli¢ed by PCR using a 5P primer (5P-
GGAAGATCTTCAGACAAGCTGAAGCAGAT-3P) containing an
in-frame BglII site and a 3P primer (5P-GGAAGATCTCTACGT-
GACCCAGAAGGTG-3P) containing an in-frame BglII site located
40 bp downstream of the stop codon. PCR reactions were carried out
with Pfu polymerase (Stratagene, La Jolla, CA, USA) by 30 cycles of
95‡C for 30 s, 60‡C for 45 s, and 72‡C for 90 s. The PCR fragment
was subcloned into the BamHI site of pGIR201protA [18] resulting in
the fusion of C6ST to the insulin signal sequence and the protein A
sequence present in the vector. An NheI fragment containing the
fusion protein was inserted into the XbaI site of the expression vector
pSVL (Amersham Pharmacia Biotech).
2.4. Expression of the soluble form of the C6ST and enzyme assay
The expression plasmid (11 Wg) was transfected into COS-1 cells on
100-mm plates using Lipofectamine (Life Technologies, Gaithersburg,
MD, USA) according to the instructions provided by the manufac-
turer. Two days after transfection, 1 ml of the culture medium was
collected and incubated with 10 Wl of IgG-Sepharose (Amersham
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Fig. 1. Nucleotide and deduced amino acid sequences of the putative human recombinant C6ST cDNA and the positions of introns. The iso-
lated cDNA contained a single open reading frame that predicts a protein composed of 479 amino acid residues. The hydropathy analysis re-
vealed the putative transmembrane hydrophobic domain which is underlined in the amino-terminal region. The presumptive polyadenylation
signal ATTAAA is boxed. The sequences are numbered relative to the translation initiation site, which begins at the ¢rst in-frame ATG codon.
The locations of introns are indicated by arrowheads.
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Fig. 1 (continued).
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Pharmacia Biotech) for 1 h at 4‡C. The beads recovered by centrifu-
gation were washed with and then resuspended in the assay bu¡er,
and tested for a sulfotransferase activity using polymer chondroitin,
various chondroitin sulfate isoforms and tetrasaccharides prepared
from chondroitin and chondroitin sulfate as sulfate acceptor sub-
strates and [35S]PAPS as a sulfate donor as described [12].
2.5. Characterization of the reaction products
The reaction products were isolated by gel ¢ltration on a column of
HITRAP desalting equilibrated with 0.25 M NH4HCO3/7% 1-prop-
anol. The radioactive peak containing the product was pooled and
evaporated to dryness. The isolated products were digested with 20
mIU of chondroitinase ABC or 5 mIU of chondroitinase B. Each
digest was analyzed by an anion-exchange HPLC on an amine-bound
silica PA03 column (YMC Co., Kyoto, Japan) as described [19]. To
con¢rm the disaccharide structure, chondro-4-sulfatase or 6-sulfatase
digestion of chondroitinase ABC digest was conducted with the re-
mainder of each 35S-labeled isolated product as described [12].
2.6. Isolation of human C6ST genomic clones
A human placenta genomic library in a VFIX II phage vector
(Stratagene, La Jolla, CA, USA) was screened with the cloned chick
C6ST cDNA fragment described above. Three independent clones
were isolated and characterized. Insert DNA fragments were initially
characterized by restriction digestion and Southern blot analysis. Hu-
man genomic DNA fragments that hybridized to the C6ST cDNA
probes were subcloned into Bluescript plasmid vectors and sequenced.
3. Results and discussion
3.1. Cloning of human C6ST cDNA
The screening of the human placenta cDNA library with
the cloned chick C6ST cDNA fragment [12] resulted in the
isolation of three independent clones that overlapped with
each other. When taken together, the combined cDNA con-
tained a long 5P-untranslated region of 435 bp, a single open
reading frame of 1437 bp encoding a protein of 479 amino
acids, and a 3P-untranslated region of 1421 bp. To clone the
full-length cDNA, the RACE cloning strategy was employed
[20]. The revealed sequence of the overlapping cDNA frag-
ments indicated that the cDNA consisted of a long 5P-un-
translated region of 440 bp, a single open reading frame of
1437 bp encoding a protein of 479 amino acids, and a very
long 3P-untranslated region of 5115 bp, including a poly(A)
tail (Fig. 1). The 5P-untranslated region had a high G+C con-
tent of 75%, which probably accounts for the di⁄culty in
de¢ning this region. The Northern blot analysis indicated
that the human C6ST mRNA was about 7.5 kb in length in
human placenta [14], suggesting that the cDNA was nearly
full-length. Database searches indicated that the amino acid
sequence displayed 74, 85 and 36% identity to the chick C6ST,
mouse C6ST and human keratan sulfate Gal-6-sulfotransfer-
ase (KSGal6ST) [21], respectively, and the highest sequence
identity was found in the COOH-terminal catalytic domain
(Fig. 2). There were four regions in which more than six
consecutive amino acid clusters were identical among the
four sequences.
3.2. Expression and characterization of a soluble form of the
human C6ST
To facilitate the functional analysis of the human C6ST, a
soluble form of the protein was generated by replacing the
¢rst 48 amino acids of the C6ST with a cleavable insulin
signal sequence and a protein A IgG binding domain as de-
scribed in Section 2, and then the soluble C6ST was expressed
in COS-1 cells as a recombinant enzyme fused with the pro-
tein A IgG binding domain. The fused enzyme expressed in
the medium was absorbed on IgG-Sepharose beads to elimi-
nate endogenous C6ST, and then the enzyme-bound beads
were used as an enzyme source. The bound fusion protein
was assayed for sulfotransferase activity using a variety of
acceptor substrates. As shown in Table 1, activity was de-
tected with polymer chondroitin and every chondroitin sulfate
isoform tested. However, the incorporated sulfate level of the
chondroitin sulfate isoforms was signi¢cantly less than that
into chondroitin. For example, the sulfate incorporation
into chondroitin sulfate D was only approximately 40% of
that incorporated into chondroitin, indicating that chondroi-
tin is a better substrate than chondroitin sulfate isoforms.
Besides, only a small amount of incorporation into chondroi-
tin sulfate E was observed since chondroitin sulfate E is the
most highly sulfated chondroitin sulfate containing the least
acceptor site. In addition, no detectable sulfotransferase activ-
ity was recovered by the a⁄nity puri¢cation from a control
pSVL transfection sample.
To identify the sulfotransferase reaction products, polymer
chondroitin and chondroitin sulfates A, B, C and D were
labeled with 35S-sulfate by incubation with [35S]PAPS as a
sulfate donor and the enzyme-bound beads as an enzyme
source, and the products from each reaction were isolated
by gel ¢ltration, then digested with chondroitinase ABC.
The digest was analyzed by an anion-exchange HPLC on an
amine-bound silica column as described in Section 2. As
shown in Fig. 3, the sulfate was incorporated exclusively
into the GalNAc C6 position in a non-sulfated disaccharide
unit, GlcA-GalNAc (Fig. 3A^E). Notably, no disulfated di-
saccharides were detected, suggesting that the enzyme did not
transfer sulfate to the C6 position of a GalNAc residue in a
monosulfated disaccharide unit, GlcA-GalNAc(4-sulfate).
Moreover, no sulfated di- or tetrasaccharides were observed
for the chondroitinase B digest of the products obtained with
chondroitin sulfate B (Fig. 3F), indicating that the enzyme did
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Table 1
Sulfotransferase activities of the recombinant C6ST towards polymer chondroitin and chondroitin sulfate isoforms
Acceptor Activitya (pmol/ml medium/h) Relative rate (%)
Chondroitin 992 100
Chondroitin sulfate A 288 29
Chondroitin sulfate B 227 23
Chondroitin sulfate C 259 26
Chondroitin sulfate D 397 40
Chondroitin sulfate E 11 1
The recombinant C6ST was incubated for 1 h with 100 Wg each of the various acceptor substrates listed under the conditions described in Section 2.
The reaction products were separated from [35S]PAPS and its degradation products by gel ¢ltration chromatography on a column of HITRAP
desalting, and were quanti¢ed by liquid scintillation counting.
aThe values represent the averages of two independent experiments.
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not transfer sulfate to the GalNAc residue in the sequence
-IdoA-GalNAc-IdoA- in chondroitin sulfate B [22]. These re-
sults together indicate that the expressed protein is C6ST with
marked speci¢city for a GlcA-GalNAc sequence. These obser-
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Table 2
Sulfotransferase activities of the recombinant C6ST towards tetrasaccharides isolated from chondroitin sulfate
Acceptor Activitya (pmol/ml medium/h)
GlcAL1-3GalNAcL1-4GlcAL1-3GalNAc 10.6
GlcAL1-3GalNAc(4-O-sulfate)L1-4GlcAL1-3GalNAc 1.7
GlcAL1-3GalNAc(6-O-sulfate)L1-4GlcAL1-3GalNAc 1.2
GlcAL1-3GalNAc(4-O-sulfate)L1-4GlcAL1-3GalNAc(4-O-sulfate) NDb
The recombinant C6ST was incubated for 3 h with 1 nmol each of the various individual tetrasaccharides listed under the conditions described in
Section 2. The reaction products were separated from [35S]PAPS and its degradation products by gel ¢ltration chromatography on a column of
Superdex 30, and were quanti¢ed by liquid scintillation counting.
aThe values represent the averages of two independent experiments.
bND, not detected (6 0.01 pmol/ml medium/h).
Fig. 2. Sequence comparison of human, chick and mouse C6STs and human KSGal6ST. The predicted amino acid sequences were aligned us-
ing the GENETYX-MAC (Ver. 9) computer program. Closed and shaded boxes indicate that the predicted amino acid in the alignment is iden-
tical among all four sequences and any three sequences, respectively. There is 74, 85 or 36% identity at the amino acid level between human
and chick C6STs, between human and mouse C6STs or between human C6ST and KSGal6ST, respectively. There are four regions in which
more than six consecutive amino acid clusters were identical among the four sequences.
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vations together with the ¢nding that the -IdoA-GalNAc(6-
sulfate)-IdoA- sequence was present in dermatan sulfate iso-
lated from human umbilical cord [23] suggested that another
as yet unidenti¢ed sulfotransferase that catalyzes the transfer
of sulfate to the C6 position of the GalNAc in the -IdoA-
GalNAc-IdoA- sequence probably exists. In fact, we have
found a sulfotransferase in fetal bovine serum that catalyzed
sulfate transfer from PAPS to a GalNAc residue in the -IdoA-
GalNAc-IdoA- sequence [24].
To further characterize the substrate speci¢city of the re-
combinant C6ST, we examined four structurally de¢ned tet-
rasaccharides. These tetrasaccharides included those isolated
from commercial chondroitin, king crab cartilage chondroitin
sulfate K and bovine tracheal cartilage chondroitin sulfate
using testicular hyaluronidase. As shown in Table 2, a non-
sulfated compound, GlcAL1-3GalNAcL1-4GlcAL1-3GalNAc,
was a better substrate than the monosulfated compounds
GlcAL1-3GalNAc(4-O-sulfate)L1-4GlcAL1-3GalNAc and
GlcAL1-3GalNAc(6-O-sulfate)L1-4GlcAL1-3GalNAc, where-
as a disulfated tetrasaccharide, GlcAL1-3GalNAc(4-O-sul-
fate)L1-4GlcAL1-3GalNAc(4-O-sulfate) showed no acceptor
activity. These 35S-labeled products obtained with the former
three tetrasaccharide acceptors were completely digested with
chondroitinase ABC, yielding quantitatively a 35S-labeled
peak at the position of v4;5HexAK1-3GalNAc(6-O-sulfate)
(data not shown). The results con¢rmed that the sulfate was
incorporated exclusively into the GalNAc C6 position in a
non-sulfated disaccharide unit, GlcA-GalNAc, as above.
Thus, the prior sulfation of the acceptor substrates has
some in£uence upon further sulfation. It will be interesting
to determine whether a preceding sulfation of saccharide res-
idues on the reducing side of oligosaccharides has a stimula-
tory e¡ect on the sulfation of the GalNAc at the non-reducing
terminus using sulfated oligosaccharides such as GalNAcL1-
4GlcAL1-3GalNAc(4-O- or 6-O-sulfate) when such oligosac-
charides become available.
We previously reported that strikingly similar patterns of
developmental change were observed for bovine serum C6ST
and keratan sulfate Gal-6-sulfotransferase activities, suggest-
ing that the two enzyme activities might be attributable to a
single enzyme molecule [25]. In fact, the recombinant C6ST
e⁄ciently utilized corneal keratan sulfate as an acceptor (data
not shown), con¢rming an earlier proposal that the single
enzyme C6ST catalyzes the sulfation of keratan sulfate as
well as that of chondroitin sulfate, as has been reported for
the chick recombinant C6ST [13].
3.3. Cloning of human C6ST gene
Our screening of a human placenta genomic library with the
cloned chick C6ST cDNA fragment resulted in the isolation
of three independent clones. Insert DNA fragments were char-
acterized by restriction digestion and Southern blot analysis.
Sequencing revealed that these three clones overlapped with
each other and covered the entire coding region of the C6ST
cDNA. As summarized in Fig. 4, the human C6ST gene spans
more than 20 kb and consists of three exons, the coding re-
gion of the gene being divided into two exons. The nucleotide
sequences of the exons were found to be completely identical
to those of the cDNA shown in Fig. 1. The intron/exon junc-
tions were found to follow the GT/AG rule and were £anked
by the conserved sequences [26].
To date, although at least eight distinct sulfotransferase
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Fig. 4. Genomic organization of the human C6ST gene. HindIII (H), EcoRI (E) and BamHI (B) restriction sites are shown as hash marks.
Exon regions are denoted by boxes. Closed boxes represent the coding sequence and open boxes denote the 5P- and 3P-untranslated sequences.
The translation initiation codon (ATG) and the termination codon (TAG) are also shown. Black horizontal bars denote the introns.
Fig. 3. Identi¢cation of the C6ST reaction products. Enzymatic re-
actions were carried out using polymer chondroitin (A), whale carti-
lage chondroitin sulfate A (B), pig skin chondroitin sulfate B (C),
shark cartilage chondroitin sulfate C (D), shark cartilage chondroi-
tin sulfate D (E), or pig skin chondroitin sulfate B (F) as acceptor
substrates under the incubation conditions described in Section 2,
and the reaction products were isolated by gel ¢ltration on a col-
umn of HITRAP desalting, and digested with chondroitinase ABC
(A^E) or chondroitinase B (F). The digests were analyzed by anion-
exchange HPLC on an amine-bound silica PA03 column as de-
scribed in Section 2. The eluate was collected at 30-s intervals
for radioactivity measurement by liquid scintillation counting. Ar-
rows indicate the elution positions of the authentic unsaturated dis-
accharides: 1, v4;5HexAK1-3GalNAc(6-O-sulfate); 2, v4;5HexAK1-
3GalNAc(4-O-sulfate); 3, v4;5HexA(2-O-sulfate)K1-3GalNAc(6-O-
sulfate); 4, v4;5HexAK1-3GalNAc(4,6-O-disulfate).
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cDNAs involved in GAG formation have been isolated [13^
15,21,27^32], the genomic organization has been elucidated
only for the human heparan sulfate N-deacetylase/N-sulfo-
transferase-1 and -2 genes [33,34]. The protein-coding se-
quence of the human heparan sulfate N-deacetylase/N-sulfo-
transferase-1 gene is distributed over 14 exons that span
approximately 35 kb in length [33]. Similarly, the protein-cod-
ing sequence of the human heparan sulfate N-deacetylase/N-
sulfotransferase-2 gene is distributed over 13 exons that span
approximately 6.5 kb in length [34]. Comparison of the ge-
nomic organization of the human heparan sulfate N-deacetyl-
ase/N-sulfotransferase-1 and -2 genes shows a similar genetic
exon-intron organization within the coding sequences [34]. In
contrast, the genomic organization of the human C6ST gene
is relatively simple, its protein-coding sequence being divided
into only two exons that span approximately 8 kb of the
genomic sequence (Fig. 4). In addition, the intron insertion
site within the protein-coding sequence is identical to that of
the chick C6ST gene (data not shown). These ¢ndings suggest
the existence of at least two evolutionarily distinct classes of
sulfotransferases involved in GAG biosynthesis.
In summary, we have characterized the human recombinant
C6ST and determined the genomic organization. Since a de-
¢ciency in C6ST activity has been reported to be associated
with a heritable form of spondyloepiphyseal dysplasia [35,36],
the present ¢ndings provide molecular tools to study the func-
tion and the regulated expression of chondroitin 6-sulfate
structure as well as the molecular mechanisms of such dis-
eases.
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